Skip to search formSkip to main contentSkip to account menu

OM 8980

Known as: OM-8980 
National Institutes of Health

Related topics

Related topics

1 relation
OM 89

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
1999
1999
Efficacy and safety of OM-8980 in patients with rheumatoid arthritis : An open-label, long-term, multicenter study
1994
1994
OM-8980
OM-8980 is a slow-acting antirheumatic drug (SAARD). It is a glycoprotein extract of Escherichia coli, with immunomodulatory… 
1993
1993
A 6-month randomized dose range study of OM-8980 in rheumatoid arthritis.
Sixty patients with active RA were evaluated over 6 months in a double-blind randomized dose range multicentre study comparing… 
Review
1993
Review
1993
Subreum (OM-8980): an anti-arthritic E. coli extract.
The results obtained with Subreum®, a peptide extract of E. coli, given orally, as a slow acting antirheumatic drug are… 
Review
1993
Review
1993
New focus on treatment for rheumatoid arthritis.
Although the pathogenesis of rheumatoid arthritis increasingly continues to be well understood, therapeutic approaches to the… 
1990
1990
OM-8980 and D-penicillamine in the treatment of rheumatoid arthritis. A 12-month double-blind randomized study.
Forty patients with active rheumatoid arthritis were included in this monocentre double-blind study comparing the therapeutic… 
Highly Cited
1989
Highly Cited
1989
OM-8980 in rheumatoid arthritis: a 6-month double blind placebo controlled multicenter study.
A new immunomodulating drug, OM-8980, was compared to placebo in a 6-month double blind multicenter trial including 107 patients… 
1989
1989
OM-8980, nouveau médicament antirhumatismal à action lente
1988
1988
A double blind multicentre study of OM-8980 and auranofin in rheumatoid arthritis.
The therapeutic efficacy of the immunomodulator OM-8980 in rheumatoid arthritis was compared with that of auranofin, an oral gold… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)